PD-1 和 PD-L1 蛋白表达可预测完全切除的肺腺癌患者的生存情况。
PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.
机构信息
Institute for Pulmonary Diseases of Vojvodina, Clinic for Thoracic Oncology, University of Novi Sad, Faculty of Medicine, Sremska Kamenica, Serbia.
Institute of Pathology, Medical University of Graz, Graz, Austria.
出版信息
Clin Lung Cancer. 2018 Nov;19(6):e957-e963. doi: 10.1016/j.cllc.2018.08.014. Epub 2018 Aug 22.
BACKGROUND
We assessed the prognostic value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in patients with completely resected lung adenocarcinoma.
PATIENTS AND METHODS
PD-1 and PD-L1 expression was determined using immunohistochemistry in formalin-fixed paraffin-embedded surgical specimens and correlated with the clinicopathologic features and survival of 161 patients with lung adenocarcinoma.
RESULTS
PD-1 expression on immune cells was observed in 71 of 159 evaluable tumor samples (45%) and was not significantly associated with the clinicopathologic features. Multivariate analyses identified PD-1 expression as an independent prognostic factor for recurrence (adjusted hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.36-0.95; P = .03) and death (adjusted HR, 0.48; 95% CI, 0.27-0.86; P = 0.01). PD-L1 expression on tumor cells was seen in 59 of 161 cases (37%) and correlated with KRAS mutation status (P = .02) and type of surgery (P = .01). PD-L1 expression was not associated with recurrence-free survival in the patients (adjusted HR, 0.90; 95% CI, 0.55-1.48; P = .68) but correlated with longer overall survival (adjusted HR, 0.54; 95% CI, 0.30-0.97; P = .04).
CONCLUSION
PD-1 and PD-L1 expression was associated with favorable overall survival in patients with completely resected adenocarcinoma of the lung.
背景
我们评估了程序性细胞死亡 1（PD-1）和程序性细胞死亡配体 1（PD-L1）在完全切除的肺腺癌患者中的预后价值。
患者和方法
使用免疫组织化学法在福尔马林固定石蜡包埋的手术标本中测定 PD-1 和 PD-L1 的表达，并将其与 161 例肺腺癌患者的临床病理特征和生存相关联。
结果
在 159 例可评估的肿瘤标本中，有 71 例（45%）观察到免疫细胞上的 PD-1 表达，且与临床病理特征无显著相关性。多变量分析确定 PD-1 表达是复发（调整后的危险比 [HR]，0.59；95%置信区间 [CI]，0.36-0.95；P =.03）和死亡（调整后的 HR，0.48；95% CI，0.27-0.86；P =.01）的独立预后因素。在 161 例病例中，有 59 例（37%）观察到肿瘤细胞上的 PD-L1 表达，且与 KRAS 突变状态（P =.02）和手术类型（P =.01）相关。PD-L1 表达与患者无复发生存期无关（调整后的 HR，0.90；95% CI，0.55-1.48；P =.68），但与总生存期较长相关（调整后的 HR，0.54；95% CI，0.30-0.97；P =.04）。
结论
PD-1 和 PD-L1 的表达与完全切除的肺腺癌患者的总体生存获益相关。
Zotero 插件